Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

This trial tests the combination of acalabrutinib (a targeted BTK inhibitor) and obinutuzumab (a monoclonal antibody against CD20) in patients with previously untreated follicular lymphoma or other slow-growing (indolent) B-cell lymphomas. The goal is to achieve remission without traditional chemotherapy. **You may be eligible if...** - You are 18 or older with previously untreated follicular lymphoma (grades 1–3a), marginal zone lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, or other indolent B-cell lymphoma - You either have low disease burden and prefer a less intensive treatment, or have high disease burden but are unwilling or unable to receive standard first-line therapy - You have at least one measurable affected lymph node or area of disease (1.5 cm or larger) **You may NOT be eligible if...** - You have received any prior treatment for your lymphoma - You have high-grade follicular lymphoma (grade 3b) or aggressive lymphoma - You have serious organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.